Diagnostic value of plasma C-type natriuretic peptide levels in determination of the duration of mesenteric ischaemia

摘要

Acute mesenteric ischaemia (AMI) causes significant morbidity and mortality if not promptly diagnosed and treated. If medical interventions are delayed, the patient may sustain serious ischaemic injury leading to bowel necrosis, so large segments of bowel may require surgical resection. Often these patients have poor clinical outcomes and suffer from complications such as malnutrition., Mesenteric ischaemia makes up 0.1% of all hospital admissions. Even though technological advances have been made in diagnostic laboratory and imaging techniques, AMI remains fatal in 60% of patients diagnosed with this condition.,Scientists have been investigating whether there are specific sensitive biomarkers that may indicate the presence of AMI., Several endothelial markers have been identified as putative biomarkers that may reveal the severity and duration over which mesenteric ischaemia has been sustained. However, markers that are effective enough for use in clinical practice have yet to be identified.Natriuretic peptides, namely atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) function in maintaining fluid and electrolyte balance as well as blood vessel tone. CNP is released by vascular endothelial cells, and this biomarker’s function in influencing vascular tone has been investigated., It has been hypothesised that CNP is an endothelium-derived hyperpolarising factor (EDHF) that specifically affects the degree of resistance in the mesenteric arteries. In this study, we aimed to investigate plasma CNP levels during early and advanced stages of mesenteric ischaemia so as to determine whether CNP levels are a good indicator of severity of AMI in a rat model.